Leidos Downgrade with PT Cut to $125 Faces Near-Term Headwinds
Jun 17, 2026, 12:53 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A downgrade with a substantial PT reduction tends to trigger multiple compression and near-term price weakness, especially when the stock is already near support and facing headwinds from DHMSM winding down and MDE recompete. Historical patterns show upgrades/downgrades often lead to follow-on selling in the weeks to months ahead, unless catalysts materialize quickly.
AI summary
What happened, with direct paths to the underlying reporting
An analyst downgraded LDOS to Neutral and trimmed the target to $125, citing deferred growth and near-term headwinds. The weakness centers on the DHMSM wind-down and MDE recompete risk, which could delay awards realization. Managed health care remains a bright spot, but rising competition may cap upside until results materialize.
Analyst Mora downgrades LDOS from Buy to Neutral; PT cut to $125.
Awards booked: $8B in 15 months; $9B more expected in next 12 months.
Growth may be deferred; DHMSM winding down and MDE recompete risk.
Managed health care standout but near-term competition could cap upside.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
